title: Low dose IL-2 increase regulatory T cells and elevate platelets in a patient with immune thrombocytopenia.
abstract: Immune thrombocytopenia (ITP) is an autoimmune disorder in which its immune system destroys platelets and leads to haemorrhage symptom. Recent studies have found that regulatory T cells (Tregs) in peripheral blood, bone marrow, and spleen were reduced in ITP patients and recovered after effective ITP therapy. Low-dose Interleukin-2 (IL-2) has been reported recently to increase Tregs and used to treat autoimmune disease including graft-versus-host disease (GVHD) after organ transplantation and HCV-related autoimmune vasculitis. However, it is unknown whether IL-2 is able to treat ITP. We have used low-dose IL-2 (1.0 million IU/day) on 5 consecutive days per week for 4 weeks in a 36-year-old patient with ITP. The result has shown that low-dose IL-2 induces expansion of Tregs significantly and increase platelet count was gradually from 36 × 109/L to maximum 85 × 109/L. No side effects of IL-2 have been found. This result suggested that low-dose of IL-2 may have therapeutic potential for ITP. © 2016 International Clinical Cytometry Society.
authors.affiliation: Department of Hematology, Hamatological Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
authors.forename: Jiakui
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Hematology, Hamatological Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
authors.forename: Yanjie
authors.initials: Y
authors.lastname: Ruan
authors.affiliation: Department of Hematology, Hamatological Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Shen
authors.affiliation: Department of Hematology, Hamatological Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
authors.forename: Qianshan
authors.initials: Q
authors.lastname: Tao
authors.affiliation: Department of Hematology, Hamatological Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
authors.forename: Huiping
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Hematology, Hamatological Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
authors.forename: Lili
authors.initials: L
authors.lastname: Tao
authors.affiliation: Department of Hematology, Hamatological Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
authors.forename: Yin
authors.initials: Y
authors.lastname: Pan
authors.affiliation: Department of Hematology, Hamatological Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
authors.forename: Huizi
authors.initials: H
authors.lastname: Fang
authors.affiliation: Centre for Transplant and Renal Research, Westmead Institute for Medical Research at University of Sydney, Sydney, Australia.
authors.forename: Yiping
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Hematology, Hamatological Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230601, People's Republic of China.
authors.forename: Zhimin
authors.initials: Z
authors.lastname: Zhai
mesh_terms: D000328:Adult; D001792:Blood Platelets / Q000187:drug effects*; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage*; D008297:Male; D010976:Platelet Count / Q000379:methods; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects*
chemical_list: D007376:Interleukin-2
keywords: immune thrombocytopenia; interleukin-2; regulatory T cells; treatment